Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Scios Nova Inc.

(SCIO)

Stone downgraded the Mountain View, Calif., company to "underperform" with a fair value of $3-$4 after Auriculin failed to

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE